欢迎来到 CSNpharm! 产品仅用于科研!
首页 400-920-2911

ERK

ERK

货号 产品名 CAS号 信息
CSN16763 XMD8-92 1234480-50-2 XMD8-92 is an inhibitor of ERK5/BMK1. The Kd values for BMK1, DCAMKL2, PLK4 and TNK1 are 80 nM, 190 nM, 600 nM and 890 nM respectively.
CSN17855 XMD17-109 1435488-37-1 XMD17-109 is a specific ERK-5 inhibitor with an EC50 4.2 μM in HEK293 cells.
CSN18540 VX-11e 896720-20-0 VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK (Extracellular Signal-Regulated Kinase) and is antitumor agent.
CSN15784 Ulixertinib   869886-67-9 Ulixertinib is a potent and reversible ERK1/ERK2 inhibitor with IC50 of < 0.3 nM for ERK2.
CSN23392 Ulixertinib HCl 1956366-10-1 Ulixertinib HCl, the salt of ulixertinib, is a reversible inhibitor of ERK1/ERK2. It can inhibit cell proliferation.
CSN13154 Tauroursodeoxycholate Sodium 35807-85-3 Tauroursodeoxycholate sodium can suppress ERK via PKCα-mediated MKP-1 induction, thus inhibiting neointimal hyperplasia of smooth muscle cells.
CSN13643 SCH772984   942183-80-4 SCH772984 is a specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.
CSN17141 Pluripotin 839707-37-8 Pluripotin is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. It maintains embryonic stem cell (ESC) self-renewal.
CSN21082 MK-8353 1184173-73-6 MK-8353, also known as SCH900353, is a potent and orally active ERK1/2 inhibitor and anticancer drug candidate currently being developed by Schering-Plough. MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models.
CSN20623 LY3214996 1951483-29-6 LY3214996 can inhibit ERK1 and ERK2 with IC50s of 5 nM.
CSN22441 KO-947 1695533-89-1 KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential clinical utility in MAPK pathway dysregulated tumors.
CSN16271 GDC-0994   1453848-26-4 GDC-0994 is highly selective for ERK1 and ERK2, with IC50 of 1.1 nM and 0.3 nM, respectively.
CSN19017 GDC-0994 HCl 2070009-58-2 GDC-0994 HCl is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.
CSN13064 FR 180204 865362-74-9 FR 180204 is a potent and selective ATP-competitive inhibitor of ERK1 and ERK2 with Ki value of 0.31 μM and 0.14 μM respectively and has IC50 values of 0.51 and 0.33 μM in enzymatic assays against ERK1 and ERK2, respectively.
CSN17601 ERK5-IN-1 1234479-76-5 ERK5-IN-1 exhibits potent inhibition of ERK5 with cellular EC50 values of 0.19 μM and enzymatic IC50 values of 0.087 μM and of LRRK2[G2019S] with enzymatic IC50 values of 0.026μM.
CSN18045 DEL-22379 181223-80-3 DEL-22379 inhibits ERK dimerization with IC50 of 0.5 μM.
CSN13519 Corynoxeine 630-94-4 Corynoxeine is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation, and is a useful and prospective compound in the prevention and treatment for vascular diseases.
CSN22365 CC-90003 1621999-82-3 CC-90003 is an irreversible inhibitor of ERK 1/2 with antitumor activity.
CSN21094 AZD0364   2097416-76-5 AZD0364 is an ERK1 and​/or ERK2 kinase for the treatment of cancer.
CSN19016 APS-2-79 2002381-25-9 APS-2-79 is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site.
CSN21221 AG-126 118409-62-4 AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM.
CSN20372 ADA-07 N/A ADA-07, a T-LAK cell-originated protein kinase (TOPK) inhibitor, is a promising chemopreventive or potential therapeutic agent against SUV-induced skin carcinogenesis that acts by specifically targeting TOPK.
CSN22695 AX 15836 2035509-96-5
<< PREV 1 NEXT >>